Cancer can go undetected for anywhere from a few months to more than a decade, depending on the type. Some slow-growing cancers, like prostate cancer, can quietly exist for 10 to 15 years or longer before causing any symptoms. Fast-growing cancers, like certain lung or pancreatic cancers, may develop and spread in under two years. The wide range comes down to how quickly the tumor doubles in size, where it’s located, and whether screening catches it before symptoms appear.
Why Some Cancers Stay Hidden for Years
A tumor starts from a single mutated cell and must divide many times before it’s large enough to cause pain, show up on a scan, or produce noticeable symptoms. Even with modern imaging like CT and MRI, the smallest tumor that can be reliably detected is about 3 millimeters across. By that point, it has already been growing for months or years at the cellular level. A lump you can feel with your fingers is typically at least 1 to 2 centimeters, meaning it contains millions of cells and has been developing even longer.
Cancer cells can also enter a dormant state, essentially pausing their growth for extended periods. Dormant cells stop dividing but remain alive, sitting quietly in tissues without triggering immune responses or forming visible masses. They retain the ability to “wake up” and start multiplying again, which is one reason cancers sometimes appear years after a person seemed healthy. This dormancy is regulated by competing chemical signals inside and around the cell. When growth-promoting signals dominate, the cells resume dividing. When suppressive signals are stronger, the cells stay frozen in place.
Tumor Doubling Times by Cancer Type
One of the clearest ways to understand detection timelines is through doubling time: how long it takes a tumor to double in volume. Faster doubling means faster progression and a shorter window before symptoms emerge. Slower doubling means a tumor can linger undetected much longer.
Research published in the AAPS Journal estimated mean doubling times across several common cancers. Non-small cell lung cancer and triple-negative breast cancer are among the fastest, each doubling roughly every 2.4 months. Colorectal cancer doubles about every 2.75 months. On the slower end, hormone receptor-positive breast cancer doubles approximately every 4.3 months, HER2-positive breast cancer every 4.1 months, and pancreatic cancer about every 5 months. These are averages for established tumors visible on imaging. Early-stage growth at the cellular level is often slower and harder to measure.
These numbers matter practically. A tumor with a 2.4-month doubling time can grow from barely detectable to dangerous in well under a year. A tumor doubling every 4 to 5 months gives screening a wider window to catch it.
Pancreatic Cancer: A Decade in the Making
Pancreatic cancer is often called a “silent” cancer because it rarely produces symptoms until it has spread. Genomic studies have mapped its progression in detail. From the first genetic mutation that starts the process, it takes an estimated 11.7 years on average for the primary tumor to fully develop. After that, another 6.8 years typically pass before metastatic subclones form within the tumor. Patients then survive an average of 2.7 years after metastasis.
That means the total timeline from the first abnormal cell to death can span roughly 20 years. The cruel irony is that most of that time passes without any detectable sign. The pancreas sits deep in the abdomen, far from the surface, and its tumors don’t press on nerves or block visible structures until they are advanced. By the time jaundice, weight loss, or back pain appear, the cancer is often already metastatic.
Colorectal Cancer: The Slowest Buildup
Colorectal cancer follows one of the longest known progression timelines. Most cases begin as a small, benign polyp in the colon or rectum that slowly accumulates genetic changes over many years before becoming cancerous. Studies modeling this process estimate that a tiny polyp (under 6 millimeters) can sit in the colon for roughly 17 to 26 years before becoming malignant. Larger polyps (over 1 centimeter) progress faster but still take an estimated 5 to 16 years to transform into invasive cancer, depending on the modeling assumptions used.
This unusually long timeline is exactly why colonoscopy screening works so well. Removing polyps during that precancerous phase effectively resets the clock. It also explains why screening guidelines recommend starting at age 45 for average-risk adults: that gives doctors a realistic chance of catching polyps before they’ve had decades to turn dangerous.
Prostate Cancer: Years of Quiet Growth
Prostate cancer is perhaps the best-known example of a cancer that can exist for years without threatening a person’s life. Many prostate tumors are indolent, meaning they grow so slowly that they never cause symptoms. Autopsy studies have consistently found prostate cancer in men who died of completely unrelated causes and never knew they had it.
Even when prostate cancer does become detectable through a PSA blood test, the timeline to serious disease is long. The median time from an elevated PSA to the development of clinical metastasis is approximately 8 years. And in some cases, cancer cells that have spread beyond the prostate enter a dormant state, sitting quietly in bone or lymph tissue for years before reactivating. This is why prostate cancer can recur a decade or more after initial treatment.
Because of this slow progression, many men with low-risk prostate cancer are monitored through active surveillance rather than treated immediately. The cancer is technically “detected,” but it may never require intervention.
Breast Cancer: A 2 to 7 Year Window
Breast cancer has a preclinical detectable phase, the period during which a tumor is large enough for screening to find it but hasn’t yet caused symptoms, that lasts roughly 2 to 7 years. This estimate comes from mammography studies in women aged 40 to 64. In practical terms, a breast tumor might be silently growing for several years before it reaches the size where a mammogram picks it up, and then it could grow for several more years before a woman notices a lump or other change.
The growth speed varies dramatically by subtype. Triple-negative breast cancer, the most aggressive form, doubles in volume about every 2.4 months. Hormone receptor-positive breast cancer, the most common form, doubles roughly every 4.3 months. This means a triple-negative tumor can go from screening-detectable to symptomatic in under a year, while a hormone-positive tumor may take two or three years to make that same leap.
What Determines Whether Cancer Gets Caught Early
Three factors control how long a cancer stays hidden. The first is biology: slow-growing, indolent cancers like many prostate and thyroid tumors can exist for a decade or more. Fast-growing cancers like certain lung cancers or triple-negative breast cancers can progress from invisible to advanced in under two years.
The second is location. Cancers in organs you can see or feel, like skin or breast, tend to be found earlier. Cancers in deep organs like the pancreas, ovaries, or kidneys have no easy external signal and often reach advanced stages before causing noticeable problems.
The third is screening. Regular screening compresses the undetected period dramatically. Mammography shortens breast cancer’s silent phase by years. Colonoscopy can catch colorectal cancer during its decade-long precancerous stage. Low-dose CT scans can identify lung nodules in high-risk individuals before symptoms develop.
Blood Tests for Earlier Detection
A newer category of screening, called multi-cancer early detection tests, analyzes blood samples for molecular signals shed by tumors. These tests aim to detect cancers that currently have no standard screening method, like pancreatic, ovarian, or liver cancer.
Performance varies widely across available tests. In clinical trials, overall sensitivity ranges from about 50% to 95%, meaning these tests catch somewhere between half and nearly all cancers present. Specificity, the ability to correctly identify people who don’t have cancer, generally falls between 89% and 99%. One of the most studied tests, Galleri, showed 51.5% overall sensitivity in clinical data, with sensitivity for stage I through III cancers at about 40.7%. Its specificity was 99.5%, meaning false positives are rare.
These numbers highlight an important reality: blood-based screening is promising but still misses a significant portion of early-stage cancers. For now, these tests are designed to complement, not replace, established screening methods like mammography and colonoscopy. The technology is advancing quickly, but no single blood draw can yet reliably catch every cancer in its earliest stages.